Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Everest and Providence Developing Omicron Variant COVID Vaccine
Shanghai Everest Medicines partnered with Providence Therapeutics, an
In September, Everest signed a $500 million two-part deal with
“We believe it is essential to develop new vaccines quickly and effectively to combat the new Omicron COVID-19 variant. We will work closely with regulatory bodies and seek the appropriate clinical studies and regulatory approvals to bring this vaccine to market as soon as possible.” said Brad Sorenson, CEO of Providence Therapeutics.
“We look forward to rapidly developing this new Omicron variant vaccine with
Everest has developed a portfolio of ten candidates with global first-in-class or best-in-class potential. The company was formed by CBC.
See our other articles on Everest.